Failure of MIF-I to affect behavioral responses in patients with parkinson's disease under l-dopa therapy
- 1 January 1979
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 63 (3), 217-222
- https://doi.org/10.1007/bf00433553
Abstract
In eight subjects with Parkinson's disease under an optimal daily dose of l-dopa, acute administration of MIF-I (200 mg i.v.) did not ameliorate either the total disability score or the intellectual test PM 38 when evaluated in comparison with the effect induced by acute administration of a placebo. Also concomitant evaluation of the effect of MIF-I on the secretion of anterior pituitary hormones which are under dopaminergic control i.e., growth hormone and prolactin, did not reveal any potentiation of the l-dopa-induced stimulus.Keywords
This publication has 26 references indexed in Scilit:
- Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1977
- Effects of L-prolyl-L-leucyl-glycine amide (MIF-I) on dopaminergic neuronsPharmacology Biochemistry and Behavior, 1976
- MIF, TRH, and simian social and motor behaviorPharmacology Biochemistry and Behavior, 1976
- POTENTIATION OF LEVODOPA EFFECT BY INTRAVENOUS L-PROLYL-L-LEUCYL-GLYCINE AMIDE IN MANThe Lancet, 1975
- Effect of Melanocyte-Stimulating Hormone-Release Inhibiting Factor (MIF) in Parkinson’s SyndromEuropean Neurology, 1974
- Luteinizing Hormone-Releasing Factor Potentiates Lordosis Behavior in Hypophysectomized Ovariectomized Female RatsScience, 1973
- Deserpidine Antagonism by a Tripeptide, L-Prolyl-L-LeucylglycinamideNeuroendocrinology, 1973
- IMPROVEMENT IN MENTAL DEPRESSION WITH DECREASED THYROTROPIN RESPONSE AFTER ADMINISTRATION OF THYROTROPIN-RELEASING HORMONEThe Lancet, 1972
- DOPA Potentiation by a hypothalamic factor, MSH release-inhibiting hormone (MIF)Life Sciences, 1971
- A Sensitive Double Antibody Immunoassay for Human Growth Hormone in PlasmaNature, 1964